Duvelisib + Nivolumab for the Treatment of MF and SS

Brief Summary:

This phase I trial identifies the best dose, possible benefits, and/or side effects of duvelisib in combination with nivolumab in treating patients with stage IIB-IVB mycosis fungoides and Sezary syndrome. Duvelisib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving duvelisib in combination with nivolumab may work better than giving each of these drugs individually, or treating with the usual approach in patients with mycosis fungoides and Sezary syndrome.

Website: https://clinicaltrials.gov/ct2/show/NCT04652960?term=Duvelisib+%2B+Nivolumab&draw=2&rank=3

Sponsors and Collaborators

National Cancer Institute (NCI)

Investigators

Principal Investigator: Neha Mehta-Shah Yale University Cancer Center LAO

Contacts and Locations

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04652960

Recruiting

Participating Locations:

Mayo Clinic
Scottsdale, AZ, United States
Principal Investigator
Allison C. Rosenthal
Contact
Site Public Contact
855-776-0015
Recruiting
University of Colorado Anschutz Medical Campus
Aurora, CO, United States
Principal Investigator
Bradley Haverkos
Contact
Site Public Contact
720-848-0650
Recruiting
Mayo Clinic - Florida
Jacksonville, FL, United States
Principal Investigator
Muhamad Alhaj Moustafa
Contact
Site Public Contact
855-766-0015
Recruiting
Dana Farber Cancer Institute
Boston, MA, United States
Principal Investigator
Eric D. Jacobsen
Contact
Site Public Contact
877-442-3324
Recruiting
Siteman Cancer Center
St. Louis, MO, United States
Principal Investigator
Neha Mehta-Shah
Contact
Site Public Contact
info@siteman.wustl.edu
800-600-3606
Recruiting
University of Pittsburgh Medical Center
Pittsburgh, PA, United States
Principal Investigator
Oleg Akilov
Contact
Site Public Contact
412-647-8073
Recruiting